Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients
- PMID: 11104564
- PMCID: PMC2363462
- DOI: 10.1054/bjoc.2000.1501
Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients
Erratum in
- Br J Cancer 2001 Mar 23;84(6):874
Abstract
The prognostic value of disseminated tumour cells derived from 353 breast cancer patients was evaluated. Disseminated tumour cells were purified from blood using a newly established method and nucleic acids were subsequently isolated. We investigated genomic imbalances (GI) such as mutation, amplification and loss of heterozygosity of 13 tumour suppressor genes and 2 proto-oncogenes using DNA from isolated minimal residual cancer cells. Significant correlations were found between genomic alterations of the DCC - and c-erbB-2 genes in disseminated breast cancer cells and actuarial relapse-free survival. Furthermore, increasing numbers of genomic imbalances measured in disseminated tumour cells were significantly associated with worse prognosis of recurrent disease. Logistic regression and Cox multivariate analysis led to the identification of genomic imbalances as an independent prognostic factor. Determination of disseminated tumour cells by genotyping of oncogenes and tumour suppressor genes seems not only to be a useful adjunct in follow up of carcinoma patients but provides also valuable additional individualized prognostic and predictive information in breast cancer patients beyond the TNM system.
Copyright 2000 Cancer Research Campaign.
Similar articles
-
Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.Anticancer Res. 2002 Jul-Aug;22(4):2493-9. Anticancer Res. 2002. PMID: 12174951
-
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.Cancer Res. 1989 Dec 1;49(23):6675-9. Cancer Res. 1989. PMID: 2573420
-
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.Clin Cancer Res. 2001 Aug;7(8):2222-7. Clin Cancer Res. 2001. Retraction in: Clin Cancer Res. 2002 Sep;8(9):3027. PMID: 11489795 Retracted.
-
Oncogenic proteins and prognostic correlations in breast cancer.In Vivo. 1993 Nov-Dec;7(6B):585-9. In Vivo. 1993. PMID: 7910764 Review. No abstract available.
-
Oncogenes and tumour suppressor genes in breast cancer.Br J Hosp Med. 1993 Nov 3-16;50(9):529-36. Br J Hosp Med. 1993. PMID: 7904528 Review.
Cited by
-
Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.Nature. 2012 Feb 22;482(7386):538-41. doi: 10.1038/nature10790. Nature. 2012. PMID: 22358843
-
Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.J Transl Med. 2012 Sep 15;10:192. doi: 10.1186/1479-5876-10-192. J Transl Med. 2012. PMID: 22978632 Free PMC article.
-
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):393-406. doi: 10.1023/a:1014730829872. J Mammary Gland Biol Neoplasia. 2001. PMID: 12013529 Review.
-
Epithelial-to-mesenchymal transitions and circulating tumor cells.J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):261-73. doi: 10.1007/s10911-010-9174-0. Epub 2010 May 7. J Mammary Gland Biol Neoplasia. 2010. PMID: 20449641 Review.
-
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues.Pharmaceuticals (Basel). 2021 Jun 21;14(6):596. doi: 10.3390/ph14060596. Pharmaceuticals (Basel). 2021. PMID: 34205827 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous